Sold as Tao. Every FDA application for this active ingredient.
As of Nov 13, 2026, FDA lists 2 applications for Troleandomycin (sold as Tao), first approved May 27, 1969, with 0 new uses approved and 0 published complete response letters.
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA
Pfizer